Hepatitis C virus (HCV) represents the major etiologic agent of non-A, non-B hepatitis. The pathological changes in hepatitis C are characterized by the histologic triad of lymphoid aggregates in portal tracts, epithelial damage of small bile ducts, and micro-and macro-vesicular steatosis. HCV antigens are visible in the cytoplasm of infected hepatocytes by immunohistochemical staining with mono-or polyclonal antibodies. These studies are important to determine the viral load and expression pattern of HCV in the infected liver. The mechanism of hepatocyte and bile duct injury in HCV infection appears to be related to the host immune response to the virus. Direct viral cytopathogenicity may also play a role.

Suitable for use in FLISA, Western Blot and Immunohistochemistry. Other applications have not been tested.

Optimal dilutions to be determined by the researcher.

Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™650 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap. 

Note: Applications are based on unconjugated antibody.

Recombinant protein corresponding to aa2190-2300 of HCV NS5a.

Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight™650.

Purified by Protein G affinity chromatography.

Recognizes HCV NS5a.